Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. TDOC
stocks logo

TDOC

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
621.91M
-3.2%
-0.302
+12.66%
627.78M
-1.99%
-0.230
+34.9%
637.01M
-0.54%
-0.217
-11.26%
Estimates Revision
The market is revising Downward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 12.71%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.59%
In Past 3 Month
Stock Price
Go Up
up Image
+12.71%
In Past 3 Month
16 Analyst Rating
up Image0
Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.46 USD with a low forecast of 7.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
14 Hold
0 Sell
Hold
up Image0
Current: 8.070
sliders
Low
7.00
Averages
8.46
High
12.00
up Image0
Current: 8.070
sliders
Low
7.00
Averages
8.46
High
12.00
BofA
Neutral
maintain
$7
2025-07-03
New
Reason
BofA
Price Target
$7
2025-07-03
New
maintain
Neutral
Reason
BofA raised the firm's price target on Teladoc to $8.75 from $7 and keeps a Neutral rating on the shares. Teladoc's recent acquisitions of Catapult and Uplift provide optionality to drive higher revenue per member, but it will take both time and execution to improve the revenue growth outlook, the analyst tells investors in a research note. BofA remains cautious on full-year guidance and momentum into 2026 but views recent acquisitions as potential catalysts for growth.
BofA
Neutral
downgrade
$8 -> $7
2025-05-28
Reason
BofA
Price Target
$8 -> $7
2025-05-28
downgrade
Neutral
Reason
BofA lowered the firm's price target on Teladoc to $7 from $8 and keeps a Neutral rating on the shares. In April, global BetterHelp MAUs declined 6.1% year-over-year, further decelerating from low single-digit declines in the prior month, according to the analyst, who cites lower peer multiples for the firm's lowered price target. The firm remains cautious on the near-term outlook, but could see investments for future growth driving greater patient engagement over time, the analyst added.
Truist
Hold
downgrade
$10 -> $9
2025-05-27
Reason
Truist
Price Target
$10 -> $9
2025-05-27
downgrade
Hold
Reason
Truist lowered the firm's price target on Teladoc to $9 from $10 and keeps a Hold rating on the shares. The firm is updating its model after the company's Q1 results with expectations of slightly lower 2026 EBITDA, the analyst tells investors in a research note. Longer term, Truist notes that with about 90M U.S. members having access to its offerings, Teladoc has the scale and depth to take advantage of various growth opportunities across the healthcare continuum.
Citi
Neutral
downgrade
$11
2025-04-25
Reason
Citi
Price Target
$11
2025-04-25
downgrade
Neutral
Reason
Citi lowered the firm's price target on Teladoc to $8.75 from $11 and keeps a Neutral rating on the shares. The firm also added an "upside 30-day short-term view" on the shares. It is likely that BetterHelp beats on sales this quarter, the analyst tells investors in a research note. Citi does not expect any change to Teladoc's guidance and, given consumer spending concerns, it thinks management will strike a cautious tone. However, given bearish sentiment, "this should be good enough" for a positive stock price reaction, contends the firm.
Jefferies
Glen Santangelo
Hold
Maintains
$10 → $8
2025-04-21
Reason
Jefferies
Glen Santangelo
Price Target
$10 → $8
2025-04-21
Maintains
Hold
Reason
B of A Securities
Allen Lutz
Hold
Maintains
$9.5 → $8
2025-04-11
Reason
B of A Securities
Allen Lutz
Price Target
$9.5 → $8
2025-04-11
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Teladoc Health Inc (TDOC.N) is -7.95, compared to its 5-year average forward P/E of -52.83. For a more detailed relative valuation and DCF analysis to assess Teladoc Health Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-52.83
Current PE
-7.95
Overvalued PE
20.13
Undervalued PE
-125.79

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
41.64
Current EV/EBITDA
6.49
Overvalued EV/EBITDA
86.83
Undervalued EV/EBITDA
-3.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.79
Current PS
0.58
Overvalued PS
10.18
Undervalued PS
-0.60

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 368.49% over the last month.
Sold
Bought

TDOC News & Events

Events Timeline

(ET)
2025-06-23
10:18:33
Teladoc 'a coiled spring' whose CEO 'just flipped the script,' Citron says
select
link
2025-04-30 (ET)
2025-04-30
16:12:57
Teladoc acquires UpLift Health for $30M in cash
select
2025-04-30
16:11:54
Teladoc sees Q2 EPS (40c)-(20c), consensus (26c)
select
Sign Up For More Events
Sign Up For More Events

News

Preview
2.0
06-26NASDAQ.COM
What's Happening With HIMS Stock?
  • Stock Price Decline: Hims & Hers Health's stock plummeted 35% after Novo Nordisk canceled their partnership, raising concerns about the company's future in the weight-loss medication market and its reliance on personalized treatments amid regulatory risks.

  • Impact of Partnership Loss: The abrupt end of the collaboration, which had previously driven a significant stock surge, highlights the challenges HIMS faces without access to Wegovy, potentially leading to further declines in stock value as investors reassess growth prospects.

Preview
8.0
06-25NASDAQ.COM
Noteworthy Tuesday Option Activity: MSTR, WGS, TDOC
  • GeneDx Holdings Corp Options Activity: GeneDx Holdings Corp (WGS) has seen significant options trading with 10,851 contracts today, representing 146.5% of its average daily volume, particularly highlighted by the $55 strike put option expiring September 19, 2025.

  • Teladoc Health Inc Options Activity: Teladoc Health Inc (TDOC) has recorded a high options volume of 63,787 contracts today, equating to 109.6% of its average daily trading volume, with notable activity in the $8 strike call option expiring July 18, 2025.

Preview
4.5
06-24NASDAQ.COM
Stocks Supported as Tensions Ease in the Middle East
  • Market Performance: Major U.S. stock indexes, including the S&P 500 and Nasdaq 100, are experiencing gains, reaching four-month highs, influenced by a tentative ceasefire between Israel and Iran that eased geopolitical risks. However, concerns over declining consumer confidence and hawkish comments from the Federal Reserve have tempered some of the optimism.

  • Sector Movements: Chipmakers and airline stocks are rallying due to falling crude oil prices, while defense contractors and precious metals mining stocks are under pressure following the ceasefire announcement. Notable stock movements include significant gains for companies like Advanced Micro Devices and Carnival Corp, alongside declines for Advanced Auto Parts and Dollar General after downgrades.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Teladoc Health Inc (TDOC) stock price today?

The current price of TDOC is 8.07 USD — it has decreased -2.65 % in the last trading day.

arrow icon

What is Teladoc Health Inc (TDOC)'s business?

Teladoc Health, Inc. provides virtual healthcare services. The Company operates through two segments: Teladoc Health Integrated Care (Integrated Care) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed primarily on a business-to-business (B2B) basis. The BetterHelp segment primarily consists of its direct-to-consumer (D2C) mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians, leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs.

arrow icon

What is the price predicton of TDOC Stock?

Wall Street analysts forecast TDOC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TDOC is 8.46 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Teladoc Health Inc (TDOC)'s revenue for the last quarter?

Teladoc Health Inc revenue for the last quarter amounts to 629.37M USD, decreased -2.59 % YoY.

arrow icon

What is Teladoc Health Inc (TDOC)'s earnings per share (EPS) for the last quarter?

Teladoc Health Inc. EPS for the last quarter amounts to -0.53 USD, increased 8.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Teladoc Health Inc (TDOC)'s fundamentals?

The market is revising Downward the revenue expectations for Teladoc Health, Inc. (TDOC) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 12.71%.
arrow icon

How many employees does Teladoc Health Inc (TDOC). have?

Teladoc Health Inc (TDOC) has 5500 emplpoyees as of July 08 2025.

arrow icon

What is Teladoc Health Inc (TDOC) market cap?

Today TDOC has the market capitalization of 1.42B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free